InvestorsHub Logo
Followers 45
Posts 6248
Boards Moderated 0
Alias Born 06/17/2009

Re: RipperMagoo1 post# 300867

Saturday, 02/27/2021 6:17:31 AM

Saturday, February 27, 2021 6:17:31 AM

Post# of 462057

Not sure how you’ve hung on mentally through the years of sp suppression and 300k+ posts.



Ripper, we knew we had to hang in there since we didn't have 2-73 available yet to help us! ;)

Actually, for me, I had seen, first, my aunt deteriorate over several years with Alzheimer's in the late 70's until her death in 1987. Then, my Dad was diagnosed with a mild form of dementia 20 years later. So, it became a passion of mine to research companies until I found the one with the best chance to contain and/or wipe out this fatal disease. I did not think about BP could do it and looked at small, incubator type firms with the thought one would be to AD like Medarex was to melanoma with Yervoy ("stolen" by BMS in 2009 for only $2.1B). Obviously, all but one biotech investment was $$ down the drain.

I've learned a lot since 2008 and since the first P2a report came out with the DPZ-naive participants' results, I've been over-the-top sometimes in my passion for 2-73 and Anavex. Many posters, from the now gone ipman to sokol to falconer to all the folks with a "J" in there name to Xena to all bio's, here have helped me and hundreds of others understand the science, the IP and patent issues, etc.

As Anavex is getting closer to AD help, we find that it is capable of helping the fight against other CNS diseases. In fact, Ripper, this quote from MJFF is the most satisfying of all, as it acknowledges blarcamesine/2-73's efficacy, that it helps patients get better and done by a third party:

"In 132 patients with Parkinson’s disease dementia, the drug significantly improved cognitive function and memory as well as REM sleep. This includes complex cognitive tasks that impact quality of life such as making a choice between similar objects and remembering daily personal experiences, which could be impaired in Parkinson’s disease. In patients with Alzheimer’s disease a Phase 2a trial demonstrated a concentration dependent response in both cognition (MMSE) and function (ADCS-ADL) over 148 weeks (longer than 3 years)."



In other words, "IT WORKS!!!"

Have a great day, Ripper ... Mine already is.

Peace,
Powerwalker



ANAVEX NOW ... RIGHT NOW ... MONO-STYLE ... for LIFE ... and for ALL AGES!!!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News